[胰高血糖素样肽-1受体激动剂与基础胰岛素的固定比例组合：文献综述]
[Fixed ratio combinations GLP-1RA and basal insulin: literature review].
作者信息
Kurkin D V, Bakulin D A, Morkovin E I, Strygin A V, Gorbunova Ju V, Volotova E V, Robertus A I, Makarenko I E, Saparova V B, Drai R V, Petrov V I
机构信息
Russian University of Medicine; Volgograd State Medical University.
Russian University of Medicine.
出版信息
Probl Endokrinol (Mosk). 2024 Feb 28;70(1):91-99. doi: 10.14341/probl13312.
Abstract
The progressive nature of type 2 diabetes mellitus leads to the need for insulin therapy in a significant proportion of patients. Very often start of insulin therapy in type 2 diabetes mellitus (T2DM) is associated with weight gain and a significant increase of hypoglycemia's risk. However, innovative options, such as fixed ratio combinations of glucagon-like peptide 1 receptor agonists (GLP-1RA) and basal insulin, minimize weight gain and hypoglycemia risks and allow a greater proportion of patients to achieve individual glycemic control goals without compromising safety parameters. This review includes a description of the randomized clinical trials, as well as the results of real clinical practice of the use of two currently existing fixed ration combinations of GLP-1RA and basal insulin - iDegLira and iGlarLixi.
摘要
2型糖尿病的进展特性导致相当一部分患者需要胰岛素治疗。2型糖尿病（T2DM）患者开始胰岛素治疗时常常伴有体重增加以及低血糖风险显著升高。然而，一些创新方案，如胰高血糖素样肽1受体激动剂（GLP-1RA）与基础胰岛素的固定比例复方制剂，可将体重增加和低血糖风险降至最低，并使更大比例的患者在不影响安全参数的情况下实现个体化血糖控制目标。本综述包括对随机临床试验的描述，以及目前两种现有的GLP-1RA与基础胰岛素固定比例复方制剂——德谷胰岛素利拉鲁肽和甘精胰岛素利司那肽在实际临床应用中的结果。
相似文献
1
[Fixed ratio combinations GLP-1RA and basal insulin: literature review].[胰高血糖素样肽-1受体激动剂与基础胰岛素的固定比例组合：文献综述]
Probl Endokrinol (Mosk). 2024 Feb 28;70(1):91-99. doi: 10.14341/probl13312.
2
Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature.基础胰岛素与胰高血糖素样肽-1受体激动剂固定比例联合治疗2型糖尿病：文献要点
Endocr Metab Immune Disord Drug Targets. 2021;21(4):626-646. doi: 10.2174/1871530320666200705211224.
3
Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.基础胰岛素/胰高血糖素样肽-1受体激动剂固定比例复方制剂（德谷胰岛素利拉鲁肽和甘精胰岛素利司那肽）用于2型糖尿病管理的理论依据、起始治疗及滴定方法
Diabetes Ther. 2017 Aug;8(4):739-752. doi: 10.1007/s13300-017-0287-y. Epub 2017 Jul 18.
4
Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira).强化血糖控制时将低血糖和体重增加降至最低：新型联合疗法（德谷胰岛素利拉鲁肽）的潜在益处
Adv Ther. 2015 May;32(5):391-403. doi: 10.1007/s12325-015-0208-2. Epub 2015 May 12.
5
Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.2 型糖尿病的固定剂量复方治疗：关于胰岛素和胰高血糖素样肽-1 受体激动剂联合治疗，您应该了解的十大要点。
Postgrad Med. 2018 May;130(4):375-380. doi: 10.1080/00325481.2018.1450058. Epub 2018 Mar 20.
6
Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.直接比较两种固定比例的胰高血糖素样肽受体激动剂和基础胰岛素在 2 型糖尿病患者的血糖和非血糖参数方面的差异。
BMC Endocr Disord. 2023 Feb 1;23(1):28. doi: 10.1186/s12902-023-01282-w.
7
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus.关于 2 型糖尿病中胰岛素-GLP-1 受体激动剂联合用药安全性的最新信息。
Expert Opin Drug Saf. 2022 Mar;21(3):349-361. doi: 10.1080/14740338.2021.1978974. Epub 2021 Oct 13.
8
Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.胰岛素甘精/利西拉来固定比例复方制剂（iGlarLixi）改善 2 型糖尿病患者的 β 细胞功能。
Diabetes Obes Metab. 2022 Jun;24(6):1159-1165. doi: 10.1111/dom.14688. Epub 2022 Mar 28.
9
Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis. commercially available 市售的
固定剂量胰岛素类似物组合（德谷胰岛素/利拉鲁肽和甘精胰岛素/利西那肽）的疗效和安全性比较：一项网络荟萃分析。
Can J Diabetes. 2023 Jun;47(4):368-377. doi: 10.1016/j.jcjd.2023.03.002. Epub 2023 Mar 22.
10
An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.在基础胰岛素治疗未达控制的2型糖尿病患者中，德谷胰岛素/利拉鲁肽（IDegLira）与甘精胰岛素/利司那肽（iGlarLixi）疗效的间接治疗比较
J Med Econ. 2018 Apr;21(4):340-347. doi: 10.1080/13696998.2017.1409228. Epub 2017 Dec 3.
本文引用的文献
1
Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis.根据每日给药时间，iGlarLixi（甘精胰岛素100 U/mL加利司那肽）治疗2型糖尿病的有效性和安全性：来自REALI汇总分析的数据。
Diabetes Ther. 2023 Apr;14(4):639-652. doi: 10.1007/s13300-023-01375-8. Epub 2023 Feb 14.
2
iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real-world study.德谷胰岛素利司那肽与预混胰岛素起始治疗用于从基础胰岛素治疗进展而来的2型糖尿病成人患者：SoliComplex真实世界研究
Diabetes Obes Metab. 2023 May;25(5):1249-1260. doi: 10.1111/dom.14974. Epub 2023 Feb 28.
3
Effectiveness, Safety, and Appropriateness in the Use of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide in Type 2 Diabetes: The ENSURE Retrospective Real-World Study.甘精胰岛素与利司那肽固定比例联合用药治疗2型糖尿病的有效性、安全性及合理性：ENSURE回顾性真实世界研究
Diabetes Ther. 2023 Jan;14(1):77-92. doi: 10.1007/s13300-022-01328-7. Epub 2022 Nov 14.
4
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).2022 年美国糖尿病协会 (ADA) 和欧洲糖尿病研究协会 (EASD) 共识报告：2 型糖尿病患者高血糖管理。
Diabetes Care. 2022 Nov 1;45(11):2753-2786. doi: 10.2337/dci22-0034.
5
Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study.IDegLira 与强化常规胰岛素治疗在成人 2 型糖尿病中的真实世界疗效比较：一项回顾性队列研究。
BMC Endocr Disord. 2022 Sep 14;22(1):229. doi: 10.1186/s12902-022-01139-8.
6
Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial.在 SoliMix 试验中，与预混 BIAsp 30 相比，iGlarLixi 可改善 2 型糖尿病患者的患者报告结局。
Diabetes Obes Metab. 2022 Dec;24(12):2364-2372. doi: 10.1111/dom.14822. Epub 2022 Aug 23.
7
Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro).罗马尼亚一项关于血糖控制不佳的 2 型糖尿病患者使用甘精胰岛素和利西那肽固定比例复方制剂（iGlarLixi）的真实世界证据：一项前瞻性队列研究（STAR.Ro）。
BMJ Open. 2022 May 27;12(5):e060852. doi: 10.1136/bmjopen-2022-060852.
8
Comparative efficacy and safety of two fixed ratio combinations in type 2 diabetes mellitus patients previously poorly controlled on different insulin regimens: a multi-centric observational study.两种固定剂量复方制剂在不同胰岛素方案血糖控制不佳的 2 型糖尿病患者中的疗效和安全性比较：一项多中心观察性研究。
Eur Rev Med Pharmacol Sci. 2022 Apr;26(8):2782-2793. doi: 10.26355/eurrev_202204_28608.
9
Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM.德谷胰岛素利拉鲁肽与德谷胰岛素门冬胰岛素治疗2型糖尿病患者的疗效比较：一项基于扫描式连续葡萄糖监测的随机交叉研究
Adv Ther. 2022 Jun;39(6):2688-2700. doi: 10.1007/s12325-022-02138-w. Epub 2022 Apr 11.
10
Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.胰岛素甘精/利西拉来固定比例复方制剂（iGlarLixi）改善 2 型糖尿病患者的 β 细胞功能。
Diabetes Obes Metab. 2022 Jun;24(6):1159-1165. doi: 10.1111/dom.14688. Epub 2022 Mar 28.
Zotero 插件